North America’s medical devices industry sees a drop of 20.8% in deal activity in Q4 2018

26 March 2019 (Last Updated March 27th, 2019 15:42)

North America’s medical devices industry sees a drop of 20.8% in deal activity in Q4 2018

North America’s medical devices industry saw a drop of 20.8% in overall deal activity during Q4 2018, when compared to the last four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 190 deals worth $6.68bn were announced for the region during Q4 2018, against the four-quarter average of 240 deals.

Of all the deal types, venture financing saw most activity in Q4 2018 with 137, representing a 72.1% share for the region.

In second place was M&A with 43 deals, followed by private equity deals with ten transactions, respectively capturing a 22.6% and 5.3% share of the overall deal activity for the quarter.

In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $4.35bn, while venture financing and private equity deals totalled $1.47bn and $863.5m, respectively.

North America medical devices industry deals in Q4 2018: Top deals

The top five medical devices deals accounted for 66.8% of the overall value during Q4 2018.

The combined value of the top five medical devices deals stood at $4.46bn, against the overall value of $6.68bn recorded for the quarter. The top announced medical devices deal tracked by GlobalData in Q4 2018 was Colfax’s $3.15bn acquisition of DJO Global.

In second place was the $504m private equity deal with Corium International by Gurnet Point Capital and in third place was ConMed’s $365m acquisition of Buffalo Filter.

The $220m acquisition of HyperBranch Medical Technology by Stryker and D1 Capital, Lux Capital, Mithril Capital Management, Partner Fund Management, Senator Investment Group, Viking Global Investors and Wellington ManagementLLP’s private equity deal with Auris Health for $220m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.